N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine | 1445894-96-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine
• 英文别名: 5-methyl-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
• CAS: 1445894-96-1
• 化学式: C₂₉H₃₉N₅O₃S
• 分子量: 537.726
• InChiKey: RCSMIXJVDRCRBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-氯乙基甲基醚 、 N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 以36%的产率得到N2-(2-isopropoxy-4-(1-(2-methoxyethyl)piperidin-4-yl)-5-methylphenyl)-N4-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine
  参考文献：
  名称：

  Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

  摘要：

  The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.

  DOI：

  10.1021/jm400402q
• 作为产物：
  描述：

  2-(异丙基磺酰基)苯胺 在 palladium diacetate 、 sodium hydride 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine
  参考文献：
  名称：

  Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

  摘要：

  The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.

  DOI：

  10.1021/jm400402q

文献信息

• [EN] A MODIFIED PROCESS FOR THE PREPARATION OF CERITINIB AND AMORPHOUS FORM OF CERITINIB<br/>[FR] PROCÉDÉ MODIFIÉ POUR LA PRÉPARATION DE CÉRITINIB ET DE FORME AMORPHE DE CÉRITINIB
  申请人：NATCO PHARMA LTD

  公开号：WO2017158619A1

  公开（公告）日：2017-09-21

  The present invention is related to an improved process for the preparation of ceritinib with high yield and high purity. The present process is cost effective and feasible in large scale production also. The present invention also related to a stable amorphous form of ceritinib and its preparation. The present invention also relates to a process for the preparation of Crystalline form A of Ceritinib.

  本发明涉及一种改进的制备高产率和高纯度的塞利替尼的工艺。本工艺成本效益高且适用于大规模生产。本发明还涉及稳定的非晶态塞利替尼及其制备方法。本发明还涉及制备塞利替尼A晶型的方法。
• [EN] PROCESS FOR THE PREPARATION OF CERITINIB USING "IN SITU" PREPARED 5-METHYL-2-(1 -METHYLETHOXY)-4-(4-PIPERIDINYL)-BENZENAMINE MONOHYDROCHLORIDE (1 :1 ) AS AN INTERMEDIATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE CÉRITINIB À L'AIDE DE MONOCHLORHYDRATE DE 5-MÉTHYL-2-(1 -MÉTHYLÉTHOXY)-4-(4-PIPÉRIDINYL)-BENZENAMINE (1/1 ) PRÉPARÉ IN SITU EN TANT QU'INTERMÉDIAIRE
  申请人：ZENTIVA KS

  公开号：WO2017041771A1

  公开（公告）日：2017-03-16

  The object of the invention is a preparation method of Ceritinib of formula (I) and its salts wherein 2-isopropylthioaniline is used in the first step. Even under mild conditions, it provides an intermediate, which is further oxidized to a sulfone in a high yield. The sulfone is subsequently transferred by means of a one-step reaction to Ceritinib of formula I in the form of a salt either through a reaction with the intermediate of formula (V) catalyzed by an acid, or in neutral conditions with its unprotected analog of formula (IX), which is in the form of the in-situ generated monohydrochloride. The product is easily isolated from the reaction as crystalline Ceritinib of formula (I) in the form of the salt with hydrochloric acid.

  该发明的目标是一种Ceritinib（化学式（I））及其盐的制备方法，其中在第一步中使用2-异丙硫氨基苯。即使在温和条件下，它也能够提供一种中间体，该中间体进一步氧化为磺酮，收率高。然后，通过一步反应将磺酮转移至Ceritinib（化学式I）的盐形式，通过与公式（V）的中间体在酸催化下反应或在中性条件下与其未保护的公式（IX）的类似物反应，后者以原位生成的单氢氯化物的形式存在。该产品易于从反应中分离出来，以盐酸的结晶Ceritinib（化学式I）的形式存在。
• COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES
  申请人：Novartis AG

  公开号：EP3038652B1

  公开（公告）日：2018-03-21
• Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
  作者：Thomas H. Marsilje、Wei Pei、Bei Chen、Wenshuo Lu、Tetsuo Uno、Yunho Jin、Tao Jiang、Sungjoon Kim、Nanxin Li、Markus Warmuth、Yelena Sarkisova、Frank Sun、Auzon Steffy、AnneMarie C. Pferdekamper、Allen G. Li、Sean B. Joseph、Young Kim、Bo Liu、Tove Tuntland、Xiaoming Cui、Nathanael S. Gray、Ruo Steensma、Yongqin Wan、Jiqing Jiang、Greg Chopiuk、Jie Li、W. Perry Gordon、Wendy Richmond、Kevin Johnson、Jonathan Chang、Todd Groessl、You-Qun He、Andrew Phimister、Alex Aycinena、Christian C. Lee、Badry Bursulaya、Donald S. Karanewsky、H. Martin Seidel、Jennifer L. Harris、Pierre-Yves Michellys

  DOI：10.1021/jm400402q

  日期：2013.7.25

  The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.